SCHEMBL964450

SCHEMBL964450

CCC(=Cc1c(C)nn(C)c1-n1nc(C)c2ccccc21)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GLS O94925 1/20 0.35
ELANE P08246 3/20 0.34
TSHR P16473 2/20 0.34
HTT P42858 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
TAAR1 Q96RJ0 1/20 0.33
KDM4E B2RXH2 3/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
RARG P13631 1/20 0.32
RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL964449 1.00 NPC1 (0.36) NPC1ALDH1A1RAB9ASMN1; SMN2GLS
SCHEMBL964008 0.81 ALDH1A1 (0.34) NPC1ALDH1A1RAB9ASMN1; SMN2TSHR
SCHEMBL964006 0.81 ALDH1A1 (0.34) NPC1ALDH1A1RAB9ASMN1; SMN2TSHR
SCHEMBL965897 0.79 ALDH1A1 (0.51) NPC1ALDH1A1RAB9ASMN1; SMN2GLS
SCHEMBL965896 0.79 ALDH1A1 (0.51) NPC1ALDH1A1RAB9ASMN1; SMN2GLS
SCHEMBL963207 0.79 PHGDH (0.36) NPC1ALDH1A1RAB9ASMN1; SMN2TSHR
SCHEMBL963205 0.79 PHGDH (0.36) NPC1ALDH1A1RAB9ASMN1; SMN2TSHR
SCHEMBL963496 0.78 HTT (0.47) ALDH1A1RAB9ASMN1; SMN2GLSHTT
SCHEMBL964447 0.77 NPC1 (0.40) NPC1ALDH1A1RAB9ASMN1; SMN2ELANE
SCHEMBL962750 0.76 ATM (0.39) ALDH1A1KDM4ECA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG NPC1 1538/4885ALDH1A1 821/4885RAB9A 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.